A 26 week randomized, open label, multi-center study of the efficacy and safety of telbivudine 600 mg once daily versus adefovir dipivoxil 10mg once daily in subjects with compensated chronic hepatitis B and sub-optimal response to at least 48 weeks of adefovir dipivoxil 10 mg.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 01 May 2012
At a glance
- Drugs Adefovir dipivoxil; Telbivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis
- 09 May 2011 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 07 Mar 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Feb 2008 New trial record.